Skip to main content

Patou Gary's Form 4 filing

Xenon Pharmaceuticals Inc. (XENE) · filed Nov 28, 2022

Accession no.
0001209191-22-058916
Filed
Nov 28, 2022
Trade date
Nov 23-25, 2022
Filing delay
5 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $138.0K. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Patou GaryCIK 0001283535Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 23, 2022Common SharesSSaleDisposed−2,057$34.33−$70,616.8123,573Direct
Nov 25, 2022Common SharesMOption exerciseAcquired+2,057$2.68+$5,512.7625,630Direct
Nov 25, 2022Common SharesFTax withholdingDisposed−120$34.37−$4,124.425,510Direct
Nov 25, 2022Common SharesSSaleDisposed−1,937$34.79−$67,388.2323,573Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 25, 2022Common SharesMOption exerciseDisposed−2,057$0.00$00Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)